Respiratory viruses impose a staggering burden on human health and economies. People spend 15-25 days annually battling infections like colds and flu, with 12.8 billion global cases in 2021 alone. These illnesses drive $600B in annual productivity losses worldwide and can trigger severe long-term conditions including heart disease, dementia, and asthma. The health toll extends far beyond immediate symptoms.

A century ago, waterborne diseases seemed equally inevitable until pharmaceutical advances and clean water infrastructure made cholera and typhoid rare. Why hasn't respiratory medicine achieved similar progress? Scientists identify two barriers: technical complexity of hundreds of mutating viral strains, and chronic underfunding that doesn't fit traditional philanthropic or commercial models. While COVID sparked temporary research bursts, funding evaporated once strain-specific vaccines emerged.

Intercept is a $500 million philanthropic initiative tackling this challenge through two complementary approaches. The program focuses on broad-spectrum preventatives (BSPs) like vaccines and nasal sprays that could block multiple viruses simultaneously, plus air cleaning technologies (ACTs) including filtration and far-UVC light for high-density spaces. Success requires both strategies working together at realistic adoption levels.

The technical sweet spot lies in preventing over 75% of symptomatic infections while maintaining safety for 60% population uptake. This demands convenient, low-side-effect treatments that avoid excessive immune stimulation. By combining individual protection with environmental pathogen reduction, Intercept aims to transform respiratory infections from inevitable nuisances into preventable conditions.